person · Reporting owner

Khattar Jack A.

Disclosed activity across 3 companies

Tapewire entity: 23273
SEC CIK: 0001539937

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
COGNITION THERAPEUTICS INCCGTX · Entity 6792	Director	June 17, 2026	June 22, 2026
SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333	Director · President, CEO	August 12, 2026	August 14, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COGNITION THERAPEUTICS INC

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	73,500	Reported balance After 2026-06-17 transaction · row 1 1 source row Row 1 · 2026-06-17 · Grant · Acquired 25,000 · Balance 73,500 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

SUPERNUS PHARMACEUTICALS, INC.

Report date August 12, 2026 · Filed August 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,258,351	Ending reported balance After 2026-08-12 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-12 · Exercise / conversion · Acquired 29,849 · Balance 1,270,993 Row 2 · 2026-08-12 · Tax withholding · Disposed 12,642 · Balance 1,258,351 F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2026-08-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-08-12 · Exercise / conversion · Disposed 29,849 · Balance 0 F2: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.
Common StockSEC Table I · non-derivative	IndirectBy the KBT Trust	958,100	Reported balance Holding disclosure · report date 2026-08-12 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 958,100

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.

F2: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

scPharmaceuticals Inc.

Report date October 07, 2025 · Filed October 07, 2025

Section 16 reporting ended · disclosed 2025-10-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-10-07 transaction · row 1 1 source row Row 1 · 2025-10-07 · Other · Disposed 5,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash, F2: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2035-06-03	Direct	Reported balance After 2025-10-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-10-07 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2034-06-11	Direct	Reported balance After 2025-10-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-10-07 · Disposition to issuer · Disposed 19,750 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2032-06-14	Direct	Reported balance After 2025-10-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-10-07 · Disposition to issuer · Disposed 16,300 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2029-06-18	Direct	Reported balance After 2025-10-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-10-07 · Disposition to issuer · Disposed 6,124 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash,

F2: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 08, 2025 Filed Sep 9, 2025 20:21 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	8,074	$0.00 Strike: $25.30	$0.00	Disclosure SEC source: 0001539937-25-000014 · wk-form4_1757449275.xml · derivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 8,074 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018 Read SEC document
September 08, 2025 Filed Sep 9, 2025 20:21 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	6,322	$46.29	$292,645.38	Disclosure SEC source: 0001539937-25-000014 · wk-form4_1757449275.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,111,983 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.40. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
September 08, 2025 Filed Sep 9, 2025 20:21 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	8,074	$25.30	$204,272.20	Disclosure SEC source: 0001539937-25-000014 · wk-form4_1757449275.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,118,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document
September 05, 2025 Filed Sep 8, 2025 20:31 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	73,176	$0.00 Strike: $25.30	$0.00	Disclosure SEC source: 0001539937-25-000012 · wk-form4_1757363472.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,574 Underlying: Common Stock · 73,176 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018. Read SEC document
September 05, 2025 Filed Sep 8, 2025 20:31 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	55,578	$46.01	$2,557,143.78	Disclosure SEC source: 0001539937-25-000012 · wk-form4_1757363472.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,110,231 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.09. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
September 05, 2025 Filed Sep 8, 2025 20:31 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	73,176	$25.30	$1,851,352.80	Disclosure SEC source: 0001539937-25-000012 · wk-form4_1757363472.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,165,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document
August 28, 2025 Filed Aug 29, 2025 20:05 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	38,779	$0.00 Strike: $12.98	$0.00	Disclosure SEC source: 0001539937-25-000010 · wk-form4_1756497941.xml · derivative · entry 7 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 38,779 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017. Read SEC document
August 28, 2025 Filed Aug 29, 2025 20:05 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	24,150	$45.12	$1,089,648.00	Disclosure SEC source: 0001539937-25-000010 · wk-form4_1756497941.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,092,633 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.26. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
August 28, 2025 Filed Aug 29, 2025 20:05 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	38,779	$12.98	$503,351.42	Disclosure SEC source: 0001539937-25-000010 · wk-form4_1756497941.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,116,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document
August 27, 2025 Filed Aug 29, 2025 20:05 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	17,195	$0.00 Strike: $12.98	$0.00	Disclosure SEC source: 0001539937-25-000010 · wk-form4_1756497941.xml · derivative · entry 6 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,779 Underlying: Common Stock · 17,195 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017. Read SEC document
August 27, 2025 Filed Aug 29, 2025 20:05 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	10,650	$45.05	$479,782.50	Disclosure SEC source: 0001539937-25-000010 · wk-form4_1756497941.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,078,004 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.10. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
August 27, 2025 Filed Aug 29, 2025 20:05 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	17,195	$12.98	$223,191.10	Disclosure SEC source: 0001539937-25-000010 · wk-form4_1756497941.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,088,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document
August 25, 2025 Filed Aug 27, 2025 20:56 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	1,611	$0.00 Strike: $12.98	$0.00	Disclosure SEC source: 0001539937-25-000008 · wk-form4_1756328164.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,974 Underlying: Common Stock · 1,611 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017. Read SEC document
August 25, 2025 Filed Aug 27, 2025 20:56 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	1,000	$45.00	$45,000.00	Disclosure SEC source: 0001539937-25-000008 · wk-form4_1756328164.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,071,459 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.01. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
August 25, 2025 Filed Aug 27, 2025 20:56 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	1,611	$12.98	$20,910.78	Disclosure SEC source: 0001539937-25-000008 · wk-form4_1756328164.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,072,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document
August 22, 2025 Filed Aug 26, 2025 20:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	2,415	$0.00 Strike: $12.98	$0.00	Disclosure SEC source: 0001539937-25-000006 · wk-form4_1756238931.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,585 Underlying: Common Stock · 2,415 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017. Read SEC document
August 22, 2025 Filed Aug 26, 2025 20:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	1,500	$45.00	$67,500.00	Disclosure SEC source: 0001539937-25-000006 · wk-form4_1756238931.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,070,848 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.01. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
August 22, 2025 Filed Aug 26, 2025 20:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	2,415	$12.98	$31,346.70	Disclosure SEC source: 0001539937-25-000006 · wk-form4_1756238931.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,072,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024. Read SEC document
August 06, 2025 Filed Aug 8, 2025 20:40 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	81,250	$0.00 Strike: $25.30	$0.00	Disclosure SEC source: 0001628280-25-039302 · wk-form4_1754685598.xml · derivative · entry 10 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,750 Underlying: Common Stock · 81,250 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018 Read SEC document
August 06, 2025 Filed Aug 8, 2025 20:40 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	60,000	$0.00 Strike: $12.98	$0.00	Disclosure SEC source: 0001628280-25-039302 · wk-form4_1754685598.xml · derivative · entry 9 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 60,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017. Read SEC document
August 06, 2025 Filed Aug 8, 2025 20:40 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	60,000	$0.00 Strike: $12.98	$0.00	Disclosure SEC source: 0001628280-25-039302 · wk-form4_1754685598.xml · derivative · entry 8 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 60,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017. Read SEC document
August 06, 2025 Filed Aug 8, 2025 20:40 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	63,500	$43.12	$2,738,120.00	Disclosure SEC source: 0001628280-25-039302 · wk-form4_1754685598.xml · nonDerivative · entry 6 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,069,933 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.56. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
August 06, 2025 Filed Aug 8, 2025 20:40 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	81,250	$25.30	$2,055,625.00	Disclosure SEC source: 0001628280-25-039302 · wk-form4_1754685598.xml · nonDerivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,133,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
August 06, 2025 Filed Aug 8, 2025 20:40 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	38,000	$42.00	$1,596,000.00	Disclosure SEC source: 0001628280-25-039302 · wk-form4_1754685598.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,052,183 Read SEC document
August 06, 2025 Filed Aug 8, 2025 20:40 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	60,000	$12.98	$778,800.00	Disclosure SEC source: 0001628280-25-039302 · wk-form4_1754685598.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,090,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
August 06, 2025 Filed Aug 8, 2025 20:40 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	38,500	$40.24	$1,549,240.00	Disclosure SEC source: 0001628280-25-039302 · wk-form4_1754685598.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,030,183 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.70. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document
August 06, 2025 Filed Aug 8, 2025 20:40 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	60,000	$12.98	$778,800.00	Disclosure SEC source: 0001628280-25-039302 · wk-form4_1754685598.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,068,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document
June 18, 2025 Filed Jun 23, 2025 23:22 UTC	COGNITION THERAPEUTICS INC CGTX · Entity 6792	GrantCommon Stock	34,000	$0.00	$0.00	Disclosure SEC source: 0001062993-25-012082 · form4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,500 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 18, 2026 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. Read SEC document
June 03, 2025 Filed Jun 5, 2025 16:45 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $3.85	$0.00	Disclosure SEC source: 0000950170-25-082429 · ownership.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 03, 2026, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
April 02, 2025 Filed Apr 3, 2025 20:27 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	16,850	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-016516 · wk-form4_1743712039.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By the KBT Trust Disclosed balance after: 1,005,600 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 16,850 shares were transferred from the KBT Trust to the Reporting Person on April 2, 2025 without consideration and are now owned directly. Read SEC document
April 02, 2025 Filed Apr 3, 2025 20:27 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	16,850	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-25-016516 · wk-form4_1743712039.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,008,683 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 16,850 shares were transferred from the KBT Trust to the Reporting Person on April 2, 2025 without consideration and are now owned directly. Read SEC document
March 10, 2025 Filed Mar 11, 2025 20:17 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionPerformance Share Unit · Derivative	35,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001628280-25-012005 · wk-form4_1741724247.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. F3 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. Read SEC document
March 10, 2025 Filed Mar 11, 2025 20:17 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Tax withholdingCommon Stock	16,805	$32.06	$538,768.30	Disclosure SEC source: 0001628280-25-012005 · wk-form4_1741724247.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 991,833 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document
March 10, 2025 Filed Mar 11, 2025 20:17 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	35,000	$0.00	$0.00	Disclosure SEC source: 0001628280-25-012005 · wk-form4_1741724247.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,008,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023. Read SEC document
March 07, 2025 Filed Mar 7, 2025 21:40 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionPerformance Share Units · Derivative	38,640	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001628280-25-011338 · wk-form4_1741383624.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,640 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. F3 · derivative.expiration_date: On February 22, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022. Read SEC document
March 07, 2025 Filed Mar 7, 2025 21:40 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Tax withholdingCommon Stock	18,581	$39.11	$726,702.91	Disclosure SEC source: 0001628280-25-011338 · wk-form4_1741383624.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 973,638 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document
March 07, 2025 Filed Mar 7, 2025 21:40 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	38,640	$0.00	$0.00	Disclosure SEC source: 0001628280-25-011338 · wk-form4_1741383624.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 992,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 17, 2025. Read SEC document
February 28, 2025 Filed Mar 4, 2025 21:21 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantPerformance Share Unit · Derivative	35,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001628280-25-009875 · wk-form4_1741123284.xml · derivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F1 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. F1 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. Read SEC document
February 20, 2025 Filed Feb 21, 2025 21:42 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantEmployee Stock Option (Right to Buy) · Derivative	331,660	$0.00 Strike: $34.59	$0.00	Disclosure SEC source: 0001628280-25-007147 · wk-form4_1740174115.xml · derivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,660 Underlying: Common Stock · 331,660 shares Expires 2035-02-20 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 19, 2026. Read SEC document
February 17, 2025 Filed Feb 19, 2025 21:54 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantPerformance Share Units · Derivative	38,640	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001628280-25-006420 · wk-form4_1740002035.xml · derivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,640 Underlying: Common Stock · 38,640 shares Expires not disclosed F1 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F1 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document
December 27, 2024 Filed Dec 30, 2024 21:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionPerformance Share Unit · Derivative	14,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001628280-24-052573 · wk-form4_1735592879.xml · derivative · entry 7 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023 and modified on December 12, 2024. F5 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023 and modified on December 12, 2024. Read SEC document
December 27, 2024 Filed Dec 30, 2024 21:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionPerformance Share Unit · Derivative	38,640	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001628280-24-052573 · wk-form4_1735592879.xml · derivative · entry 6 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,640 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F4 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document
December 27, 2024 Filed Dec 30, 2024 21:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Tax withholdingCommon Stock	6,666	$35.59	$237,242.94	Disclosure SEC source: 0001628280-24-052573 · wk-form4_1735592879.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 953,579 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document
December 27, 2024 Filed Dec 30, 2024 21:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	14,000	$0.00	$0.00	Disclosure SEC source: 0001628280-24-052573 · wk-form4_1735592879.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 960,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023. Read SEC document
December 27, 2024 Filed Dec 30, 2024 21:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Tax withholdingCommon Stock	18,567	$35.59	$660,799.53	Disclosure SEC source: 0001628280-24-052573 · wk-form4_1735592879.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 946,245 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document
December 27, 2024 Filed Dec 30, 2024 21:08 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	38,640	$0.00	$0.00	Disclosure SEC source: 0001628280-24-052573 · wk-form4_1735592879.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 964,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024. Read SEC document
December 23, 2024 Filed Dec 26, 2024 13:42 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantPerformance Share Unit · Derivative	38,640	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001628280-24-052397 · wk-form4_1735220518.xml · derivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,640 Underlying: Common Stock · 38,640 shares Expires not disclosed F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document
December 23, 2024 Filed Dec 26, 2024 13:42 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantPerformance Share Unit · Derivative	14,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001628280-24-052397 · wk-form4_1735220518.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires not disclosed F1 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023 and modified on December 12, 2024. F1 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023 and modified on December 12, 2024. Read SEC document
November 08, 2024 Filed Nov 12, 2024 21:11 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	125,000	$0.00 Strike: $9.13	$0.00	Disclosure SEC source: 0001628280-24-047142 · wk-form4_1731445884.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in four equal installments beginning on March 3, 2016. Read SEC document
November 08, 2024 Filed Nov 12, 2024 21:11 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	SaleCommon Stock	125,000	$36.29	$4,536,250.00	Disclosure SEC source: 0001628280-24-047142 · wk-form4_1731445884.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 926,172 F1 · shares: The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.87 to $36.66. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.